Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases

Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases

Bibliographic Details
Main Authors: Jordi Remon, MD, María Castro-Henriques, Laura Esteller, Josep Vives
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:JTO Clinical and Research Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320301429
id doaj-0358de9fa0ad4085bc935d2c036114ec
record_format Article
spelling doaj-0358de9fa0ad4085bc935d2c036114ec2021-03-19T07:29:36ZengElsevierJTO Clinical and Research Reports2666-36432021-01-0121100096Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal MetastasesJordi Remon, MD0María Castro-Henriques1Laura Esteller2Josep Vives3Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Delfos, HM Hospitales, Barcelona, Spain; Corresponding author. Address for correspondence: Jordi Remon, MD, Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Delfos, HM Hospitales, Avinguda Vallcarca, 151, 08023 Barcelona, Spain.Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Delfos, HM Hospitales, Barcelona, SpainDepartment of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Delfos, HM Hospitales, Barcelona, SpainDepartment of Radiology, Hospital HM Delfos, HM Hospitales, Barcelona, Spainhttp://www.sciencedirect.com/science/article/pii/S2666364320301429
collection DOAJ
language English
format Article
sources DOAJ
author Jordi Remon, MD
María Castro-Henriques
Laura Esteller
Josep Vives
spellingShingle Jordi Remon, MD
María Castro-Henriques
Laura Esteller
Josep Vives
Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases
JTO Clinical and Research Reports
author_facet Jordi Remon, MD
María Castro-Henriques
Laura Esteller
Josep Vives
author_sort Jordi Remon, MD
title Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases
title_short Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases
title_full Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases
title_fullStr Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases
title_full_unstemmed Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases
title_sort combination of atezolizumab, bevacizumab, and chemotherapy (impower 150) in a patient with nsclc having leptomeningeal metastases
publisher Elsevier
series JTO Clinical and Research Reports
issn 2666-3643
publishDate 2021-01-01
url http://www.sciencedirect.com/science/article/pii/S2666364320301429
work_keys_str_mv AT jordiremonmd combinationofatezolizumabbevacizumabandchemotherapyimpower150inapatientwithnsclchavingleptomeningealmetastases
AT mariacastrohenriques combinationofatezolizumabbevacizumabandchemotherapyimpower150inapatientwithnsclchavingleptomeningealmetastases
AT lauraesteller combinationofatezolizumabbevacizumabandchemotherapyimpower150inapatientwithnsclchavingleptomeningealmetastases
AT josepvives combinationofatezolizumabbevacizumabandchemotherapyimpower150inapatientwithnsclchavingleptomeningealmetastases
_version_ 1724213268692598784

Similar Items